Diazoxide
Orphan DrugFDA Approved, EMA Approved
Contents
Description
Diazoxide is a potassium channel activator that inhibits insulin secretion from pancreatic beta cells. It is the primary medical therapy for congenital hyperinsulinism, including forms caused by SUR1 deficiency. The drug helps prevent severe hypoglycemia in affected patients.
Indications & Therapeutic Use
congenital hyperinsulinism, hyperinsulinemic hypoglycemia, autosomal dominant hyperinsulinism
Global Availability (6 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Diazoxide — GNH India
22 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Diazoxide
25mgcapsuleJapan
Diazoxide Solution for Injection
300mg/20mLinjectionAustralia
DIAZOXIDE oral suspension
50mg/ml 30mlsuspensionUSA
Eudemine
EU
Eudemine 50mg-UK
50mgtabletUK
Proglicem
100mgcapsuleItaly
Proglicem 100mg
100mgcapsuleGermany
Proglicem 25mg
25mgcapsuleSwitzerland
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
Fulfilment Partner
Diazoxide
| Generic Name | diazoxide |
| Brands | 1 brand available |
| Active Ingredient | diazoxide |
| Drug Class | congenital hyperinsulinism |
| Manufacturer | Teva Pharmaceuticals |
| Dosage Forms | Oral suspension, 50mg/mL |
| Medical Code | C01BD01 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Clinical Trial | NCT00000611 |
| Countries | 6 countries |
Authority Signals
Last Verified3/21/2026
Data ConfidenceHigh (AI + Pharmacist)
Source Citations7 Validated Nodes